Fundraising FoxBiotechnology Value Fund — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Numabnumab.comin𝕏Jan 2025 · $55M
Numab develops multispecific antibody-based therapeutics using its proprietary λ-Cap and MATCH discovery and engineering platforms, aiming to improve on first-generation antibody therapies in potency, stability, effect duration, and safety.
BiotechDeep Tech
David Urech(Founder)in
Co-investorsEisai Innovation, Inc.HBM Healthcare InvestmentsHBM PartnersBlackRockForbionNovo Holdings+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.